We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for... Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody. Show more
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive...
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (βEledonβ) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -5.56900726392 | 4.13 | 4.17 | 3.76 | 272479 | 3.92433107 | CS |
4 | 0.33 | 9.24369747899 | 3.57 | 5.54 | 3.2 | 973719 | 4.04360229 | CS |
12 | 1.01 | 34.9480968858 | 2.89 | 5.54 | 2.375 | 387413 | 3.89009125 | CS |
26 | 0.8 | 25.8064516129 | 3.1 | 5.54 | 2.3 | 242073 | 3.62088505 | CS |
52 | 2.7 | 225 | 1.2 | 5.54 | 1.1099 | 185260 | 3.09621888 | CS |
156 | -1.39 | -26.2759924386 | 5.29 | 5.54 | 1.07 | 108471 | 2.87718431 | CS |
260 | -11.9 | -75.3164556962 | 15.8 | 22.91 | 1.07 | 99034 | 3.89760094 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions